A Study of BYL719 in Adult Patients With Advanced Solid Malignancies.

Trial Profile

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Alpelisib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 12 Sep 2017 Results assessing food effect on pharmacokinetics of alpelisib and prliminary effecacy (n=33) presented at the 42nd European Society for Medical Oncology Congress
    • 26 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Aug 2015 Planned number of patients changed from 36 to 34 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top